1. Home
  2. RVPH vs CTMX Comparison

RVPH vs CTMX Comparison

Compare RVPH & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RVPH
  • CTMX
  • Stock Information
  • Founded
  • RVPH 2006
  • CTMX 2008
  • Country
  • RVPH United States
  • CTMX United States
  • Employees
  • RVPH N/A
  • CTMX N/A
  • Industry
  • RVPH Biotechnology: Pharmaceutical Preparations
  • CTMX Biotechnology: Pharmaceutical Preparations
  • Sector
  • RVPH Health Care
  • CTMX Health Care
  • Exchange
  • RVPH Nasdaq
  • CTMX Nasdaq
  • Market Cap
  • RVPH 88.0M
  • CTMX 62.3M
  • IPO Year
  • RVPH N/A
  • CTMX 2015
  • Fundamental
  • Price
  • RVPH $1.80
  • CTMX $0.80
  • Analyst Decision
  • RVPH Strong Buy
  • CTMX Buy
  • Analyst Count
  • RVPH 5
  • CTMX 6
  • Target Price
  • RVPH $11.40
  • CTMX $5.77
  • AVG Volume (30 Days)
  • RVPH 1.6M
  • CTMX 731.5K
  • Earning Date
  • RVPH 11-14-2024
  • CTMX 03-10-2025
  • Dividend Yield
  • RVPH N/A
  • CTMX N/A
  • EPS Growth
  • RVPH N/A
  • CTMX N/A
  • EPS
  • RVPH N/A
  • CTMX 0.16
  • Revenue
  • RVPH N/A
  • CTMX $126,617,000.00
  • Revenue This Year
  • RVPH N/A
  • CTMX $22.55
  • Revenue Next Year
  • RVPH N/A
  • CTMX N/A
  • P/E Ratio
  • RVPH N/A
  • CTMX $4.93
  • Revenue Growth
  • RVPH N/A
  • CTMX 33.66
  • 52 Week Low
  • RVPH $0.60
  • CTMX $0.75
  • 52 Week High
  • RVPH $4.50
  • CTMX $5.85
  • Technical
  • Relative Strength Index (RSI)
  • RVPH 45.36
  • CTMX 41.61
  • Support Level
  • RVPH $1.97
  • CTMX $0.75
  • Resistance Level
  • RVPH $2.14
  • CTMX $0.98
  • Average True Range (ATR)
  • RVPH 0.16
  • CTMX 0.06
  • MACD
  • RVPH -0.02
  • CTMX 0.00
  • Stochastic Oscillator
  • RVPH 29.29
  • CTMX 20.13

About RVPH Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Share on Social Networks: